Harmonigenic™ Corporation was founded to guide from the lab to the clinic, a University of Rochester discovery that if validated will provide better outcomes for cancer patients including better quality of life and lower overall cost by directing earlier treatment for those who have not clinically progressed to Stage IV but are are at high risk for recurrence as Stage IV metastatic cancer.
Stories connect us all to this experience which has to get personal if precision medicine remains relevant as personalized medicine.
Who we help
We are dedicated improving the accuracy of metastatic cancer diagnosis with better treatment decisions that provide better outcomes for cancer patients including better quality of life.
Heat map of the raw data from collagen fibers in one patient sample from the publication by Burke, K. et al. Using Second Harmonic Generation to Predict Patient Outcome in Solid Tumors, Published BMC Cancer(2015).
Innovative Technology
We are developing an assay of collagen in cancer tissue called OPTIM (Optical Prediction of Time Interval to Metastasis). OPTIM predicts which cancers have already metastasized to distant sites and should receive early targeted treatment if avaialble and which have a much lower risk of recurrence.